Usmarapride

Last updated

Usmarapride
Usmarapride structure.png
Clinical data
Other namesSUVN-D4010; SUVN-D-4010
Routes of
administration 		Oral [1]
Drug class Serotonin 5-HT4 receptor agonist
ATC code
  • None
Identifiers
  • 2-[1-(3-methoxypropyl)piperidin-4-yl]-5-(1-propan-2-ylindazol-3-yl)-1,3,4-oxadiazole
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C21H29N5O2
Molar mass 383.496 g·mol−1
3D model (JSmol)
  • CC(C)N1C2=CC=CC=C2C(=N1)C3=NN=C(O3)C4CCN(CC4)CCCOC
  • InChI=1S/C21H29N5O2/c1-15(2)26-18-8-5-4-7-17(18)19(24-26)21-23-22-20(28-21)16-9-12-25(13-10-16)11-6-14-27-3/h4-5,7-8,15-16H,6,9-14H2,1-3H3
  • Key:DWTFBJGTRBMHPG-UHFFFAOYSA-N

Usmarapride (INN Tooltip International Nonproprietary Name; developmental code name SUVN-D4010) is a serotonin 5-HT4 receptor agonist which is or was under development for the treatment of cognitive deficits in Alzheimer's disease and schizophrenia. [1] [2] [3] It is taken orally. [1]

Contents

Pharmacology

The drug is a potent and selective partial agonist of the serotonin 5-HT4 receptor. [2] [3] It is highly selective against the serotonin 5-HT3 receptor and other closely related receptors. [2] The drug shows cognition- and memory-enhancing effects, neuroprotective effects, and antidepressant-like effects in preclinical research. [2] [3] [4] Its pharmacokinetics and pharmacodynamics have been evaluated in humans. [2] [5] In terms of chemical structure, the drug is an indazole derivative. [6]

Development

Usmarapride is under development by Suven Life Sciences. [1] As of September 2023, no recent development has been reported for treatment of Alzheimer's disease and schizophrenia. [1] The drug has reached phase 1 clinical trials for both of these indications. [1]

References

  1. 1 2 3 4 5 6 "Usmarapride - Suven Life Sciences". AdisInsight. 28 September 2023. Retrieved 1 October 2025.
  2. 1 2 3 4 5 Nirogi R, Mohammed AR, Shinde AK, Gagginapally SR, Kancharla DM, Ravella SR, et al. (August 2021). "Discovery and Preclinical Characterization of Usmarapride (SUVN-D4010): A Potent, Selective 5-HT4 Receptor Partial Agonist for the Treatment of Cognitive Deficits Associated with Alzheimer's Disease". J Med Chem. 64 (15): 10641–10665. doi:10.1021/acs.jmedchem.1c00703. PMID   34251799.
  3. 1 2 3 Nirogi R, Grandhi VR, Medapati R, Ganuga N, Abraham R, Thentu JB, et al. (May 2023). "Usmarapride (SUVN-D4010), a 5-HT4 receptor partial agonist for the potential treatment of Alzheimer's disease: Behavioural, neurochemical and pharmacological profiling". Eur J Pharmacol. 947 175625. doi:10.1016/j.ejphar.2023.175625. PMID   36997046.
  4. ↑ Abraham R, Subramanian R, Rasheed MA, Ravella SR, Malleshwari D, Thentu JB, et al. (2022). "Usmarapride Oxalate (SUVN-D4010): A Serotonin-4 Receptor Partial Agonist for the Treatment of Cognitive Disorders". Alzheimer's & Dementia. 18 (S10) e062167. doi:10.1002/alz.062167. ISSN   1552-5260 . Retrieved 1 October 2025.
  5. ↑ Nirogi R, Bhyrapuneni G, Muddana NR, Goyal VK, Pandey SK, Mohammed AR, et al. (May 2021). "First-in-Human Studies to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Novel 5-HT4 Partial Agonist, SUVN-D4010, in Healthy Adult and Elderly Subjects". Clin Drug Investig. 41 (5): 469–482. doi:10.1007/s40261-021-01027-4. PMID   33788154.
  6. ↑ Dallemagne P, Rochais C (July 2021). "5-HT4R modulators: a patent landscape". Pharm Pat Anal. 10 (4): 179–181. doi:10.4155/ppa-2021-0017. PMID   34365797.



This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.